Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications.
Luvometinib is an oral small molecule drug that belongs to the MET kinase inhibitor class. It is mainly used to treat patients with tumors carrying specific gene mutations, such as advanced or metastatic cancers in non-small cell lung cancer (NSCLC) driven by MET exon14 skipping mutations.
